Skip to main content
. 2022 Sep 16;82(22):4288–4298. doi: 10.1158/0008-5472.CAN-21-2483

Figure 2.

Figure 2. Dual masking of the anti-EGFR and anti-CD3 binding domains attenuates binding of CI107 to EGFR and CD3 expressed on the surface of cells. HT29 (A) HCT116 (B), or Jurkat (C) cells were incubated with increasing concentrations of CI107 or protease-activated TCB (Act-TCB), and binding was assessed by flow cytometry.

Dual masking of the anti-EGFR and anti-CD3 binding domains attenuates binding of CI107 to EGFR and CD3 expressed on the surface of cells. HT29 (A), HCT116 (B), or Jurkat (C) cells were incubated with increasing concentrations of CI107 or protease-activated TCB (Act-TCB), and binding was assessed by flow cytometry.